Biogen advances Alzheimer's drug to late-stage trial despite disappointing data
A Biogen facility in Cambridge, Massachusetts.Brian Snyder | ReutersBiogen plans to advance an experimental drug for Alzheimer's disease to late-stage...
Eli Lilly and Co
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark,...
Weight loss and hair loss: The growing hair treatment market from GLP-1s
When Branneisha Cooper first began taking GLP-1 injection Mounjaro in late 2022, she heard online that she could experience temporary...
Dow rallies 700 points, S&P 500 hits new high as strong Alphabet, Caterpillar earnings overshadow Iran worries: Live updates
Traders works on the floor of the New York Stock Exchange (NYSE) at the opening bell in New York on...
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Eli Lilly on Thursday reported first-quarter earnings and revenue that blew past estimates and hiked its full-year sales outlook by...
Stocks making the biggest moves premarket: Meta, Eli Lilly, Caterpillar, Amazon & more
Check out the companies making the biggest moves in premarket trading: Meta Platforms — The Facebook parent dropped 9% after...
Cramer's week ahead: Record highs meet a pivotal week for tech earnings
Key PointsCNBC’s Jim Cramer said the market has become a "beast", driven by a powerful rally in data center and...
Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more
These are the stocks posting the largest moves in midday trading. Source link
Amazon launches GLP-1 weight loss program, promising'fast, convenient' access
Amazon GLP-1 treatmentSource: Amazon Inc. Amazon is pushing deeper into the booming weight loss market, unveiling Tuesday a new program...
Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time...
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday.Lilly...
Inside India newsletter: Small towns are powering e-commerce's fastest-growing market, dominated by Amazon, Walmart unit
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of "Inside India" — your...
As millions lose weight on GLP-1s, they're starting to turn to retailers to refresh their wardrobes
Michelle Suter has worn mostly big and baggy clothing for years. The 63-year-old retiree who lives in a suburb of...
Inside India newsletter: Tariffs and Iran war threaten India's $100 billion garments export goal
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of "Inside India" — your...
Novo Nordisk's explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight "the right way," Jane Zuckerman realized that "putting in the work just wasn't...
Trump tariff fallout: Some industries grapple with lingering effects one year later
A year after President Donald Trump declared his "liberation day" and imposed sweeping tariffs on imports, kicking off a wave...
Inside India newsletter: The worst might not be over for Indian equities
Hello, this is Priyanka Salve, writing to you from Singapore. Welcome to the latest edition of "Inside India" — your...
Stocks making the biggest moves midday: Eli Lilly, Hasbro, Philip Morris, Intel, Micron & more
These are the stocks posting the largest moves in midday trading. Source link
FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market
The U.S. Food and Drug Administration approved Eli Lilly's GLP-1 pill, the company said, a major milestone for the Indianapolis-based...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025.Antranik Tavitian |...
